See more : SHL Telemedicine Ltd. (SHLTN.SW) Income Statement Analysis – Financial Results
Complete financial analysis of OraSure Technologies, Inc. (OSUR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of OraSure Technologies, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Landmark Infrastructure Partners LP (LMRKN) Income Statement Analysis – Financial Results
- Pexip Holding ASA (PEXIP.OL) Income Statement Analysis – Financial Results
- Guangdong Kitech New Material Holding Co.,Ltd. (300995.SZ) Income Statement Analysis – Financial Results
- Pacific Valley Bancorp (PVBK) Income Statement Analysis – Financial Results
- NHOA S.A. (0RA5.L) Income Statement Analysis – Financial Results
OraSure Technologies, Inc. (OSUR)
About OraSure Technologies, Inc.
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND genomics laboratory services. In addition, the company provides ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; offers Colli-Pee collection device for the volumetric collection of first void urine; and manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the academic research and commercial applications, including ancestry, disease risk management, lifestyle, and animal testing. Further, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 405.47M | 387.48M | 233.67M | 171.72M | 154.61M | 181.74M | 167.06M | 128.20M | 119.72M | 106.46M | 98.94M | 87.82M | 81.88M | 75.02M | 77.03M | 71.10M | 82.69M | 68.15M | 69.37M | 54.01M | 40.45M | 32.01M | 32.57M | 30.10M | 10.10M | 9.80M | 9.40M | 68.70M | 5.00M | 4.80M | 3.30M | 3.00M | 3.80M | 3.60M | 3.20M |
| Cost of Revenue | 226.05M | 239.84M | 116.07M | 69.85M | 60.02M | 68.13M | 68.11M | 40.17M | 39.43M | 39.84M | 40.35M | 32.25M | 30.16M | 27.66M | 29.90M | 29.98M | 32.40M | 24.76M | 27.97M | 22.14M | 16.06M | 12.89M | 12.33M | 9.00M | 3.10M | 3.00M | 2.80M | 58.60M | 4.90M | 5.60M | 1.70M | 1.20M | 1.90M | 2.00M | 4.20M |
| Gross Profit | 179.42M | 147.64M | 117.60M | 101.87M | 94.58M | 113.61M | 98.96M | 88.03M | 80.29M | 66.62M | 58.59M | 55.57M | 51.72M | 47.36M | 47.13M | 41.13M | 50.28M | 43.40M | 41.39M | 31.87M | 24.39M | 19.12M | 20.24M | 21.10M | 7.00M | 6.80M | 6.60M | 10.10M | 100.00K | -800.00K | 1.60M | 1.80M | 1.90M | 1.60M | -1.00M |
| Gross Profit Ratio | 44.25% | 38.10% | 50.33% | 59.32% | 61.18% | 62.51% | 59.23% | 68.66% | 67.07% | 62.58% | 59.22% | 63.28% | 63.16% | 63.13% | 61.19% | 57.84% | 60.81% | 63.68% | 59.67% | 59.00% | 60.29% | 59.74% | 62.14% | 70.10% | 69.31% | 69.39% | 70.21% | 14.70% | 2.00% | -16.67% | 48.48% | 60.00% | 50.00% | 44.44% | -31.25% |
| Research & Development | 33.73M | 36.24M | 34.17M | 31.03M | 19.63M | 16.25M | 13.37M | 9.75M | 11.65M | 12.06M | 10.93M | 12.45M | 18.41M | 13.19M | 13.37M | 20.26M | 14.14M | 8.65M | 5.27M | 6.06M | 8.00M | 8.27M | 9.39M | 10.40M | 4.00M | 2.90M | 4.20M | 4.50M | 6.80M | 6.10M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 58.19M | 68.21M | 50.33M | 42.65M | 35.29M | 38.33M | 29.32M | 28.36M | 25.49M | 23.75M | 21.65M | 22.31M | 20.33M | 16.79M | 18.30M | 37.20M | 37.37M | 29.29M | 28.55M | 27.16M | 17.68M | 14.39M | 14.73M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 36.32M | 49.24M | 44.75M | 34.46M | 31.87M | 30.61M | 28.53M | 29.65M | 35.09M | 41.12M | 46.47M | 37.09M | 22.38M | 20.73M | 21.22M | 20.92B | 20.06B | 15.92B | 16.06B | 15.15B | 10.76B | 8.07B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 92.18M | 117.44M | 95.08M | 77.11M | 67.16M | 68.93M | 57.85M | 58.01M | 60.58M | 64.87M | 68.12M | 59.40M | 42.71M | 37.52M | 39.52M | 37.20M | 37.37M | 29.29M | 28.55M | 27.16M | 17.68M | 14.39M | 14.73M | 13.81M | 5.70M | 5.40M | 6.70M | 9.80M | 11.20M | 7.80M | 13.90M | 8.20M | 6.10M | 4.40M | 1.40M |
| Other Expenses | 0.00 | 6.48M | 872.00K | 1.65M | 2.72M | 3.29M | 794.00K | 58.00K | 774.00K | 531.00K | 200.00K | -242.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.10M | 700.00K | 700.00K | 700.00K | 1.30M | 1.50M | 1.20M | 1.10M | 1.20M | 900.00K | 500.00K | 300.00K |
| Operating Expenses | 146.74M | 153.68M | 129.25M | 108.14M | 86.79M | 85.18M | 71.22M | 67.76M | 72.24M | 76.93M | 79.05M | 71.84M | 61.12M | 50.71M | 52.89M | 57.46M | 51.50M | 37.94M | 33.82M | 33.22M | 25.68M | 22.66M | 24.12M | 26.31M | 10.40M | 9.00M | 11.60M | 15.60M | 19.50M | 15.10M | 15.00M | 9.40M | 7.00M | 4.90M | 1.70M |
| Cost & Expenses | 372.79M | 393.52M | 245.32M | 178.00M | 146.81M | 153.31M | 139.33M | 107.93M | 111.66M | 116.77M | 119.40M | 104.09M | 91.28M | 78.37M | 82.79M | 87.44M | 83.91M | 62.69M | 61.79M | 55.36M | 41.74M | 35.55M | 36.46M | 35.31M | 13.50M | 12.00M | 14.40M | 74.20M | 24.40M | 20.70M | 16.70M | 10.60M | 8.90M | 6.90M | 5.90M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 63.99K | 151.76K | 737.89K | 3.08B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 10.43M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 172.00K | 316.31K | 316.19K | 361.19K | 345.77K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.52M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 20.94M | 14.00M | 11.66M | 9.39M | 7.34M | 6.45M | 6.40M | 5.69M | 5.70M | 6.31M | 6.49M | 7.25M | 4.89M | 3.01M | 3.05M | 3.39M | 2.74M | 1.92M | 2.35M | 2.49M | 2.58M | 2.18M | 2.00M | 2.10M | 700.00K | 700.00K | 700.00K | 1.30M | 1.50M | 1.20M | 1.10M | 1.20M | 900.00K | 500.00K | 300.00K |
| EBITDA | 64.35M | 10.29M | 9.00K | 3.44M | 15.53M | 34.88M | 34.14M | 26.01M | 8.06M | -4.00M | -13.91M | -9.09M | -4.50M | -168.49K | -5.02M | -5.02M | 1.52M | 7.39M | 9.92M | 1.13M | 1.29M | -1.36M | -1.89M | -4.42M | -2.70M | -1.50M | -4.30M | -4.20M | -10.10M | -14.70M | -12.30M | -6.40M | -4.20M | -2.80M | -2.40M |
| EBITDA Ratio | 15.87% | 2.81% | -5.62% | -4.29% | 3.05% | 19.62% | 12.95% | 15.81% | 11.49% | -8.92% | -22.51% | -10.27% | -11.10% | -4.28% | -2.57% | -25.02% | 0.23% | 10.98% | 14.22% | 2.19% | 3.34% | -4.25% | -4.73% | 13.02% | -26.73% | -19.39% | -54.26% | -13.97% | -376.00% | -308.33% | -333.33% | -223.33% | -115.79% | -88.89% | -81.25% |
| Operating Income | 54.08M | -4.67M | -11.65M | -6.28M | -3.02M | 28.43M | 40.24M | 20.27M | 8.06M | -4.80M | -12.16M | -16.27M | -9.40M | -3.35M | -8.79M | -16.33M | -1.22M | 5.46M | 7.57M | -1.36M | -1.29M | -3.54M | -4.33M | -12.81M | -3.40M | -2.20M | -5.00M | -5.50M | -19.40M | -15.90M | -13.40M | -7.60M | -5.10M | -3.30M | -2.70M |
| Operating Income Ratio | 13.34% | -1.20% | -4.99% | -3.65% | -1.95% | 15.64% | 24.09% | 15.81% | 6.73% | -4.51% | -12.29% | -18.53% | -11.48% | -4.47% | -11.42% | -22.97% | -1.47% | 8.02% | 10.92% | -2.51% | -3.18% | -11.06% | -13.30% | -42.56% | -33.66% | -22.45% | -53.19% | -8.01% | -388.00% | -331.25% | -406.06% | -253.33% | -134.21% | -91.67% | -84.38% |
| Total Other Income/Expenses | 2.18M | -9.63M | 872.00K | 1.65M | 2.72M | 3.29M | 794.00K | 58.00K | 774.00K | 531.00K | 200.00K | -242.00K | -312.57K | -142.84K | 357.15K | 7.58M | 5.51M | 3.60M | 2.15M | 797.04K | 176.80K | 198.06K | 633.49K | 90.89K | 200.00K | 400.00K | 800.00K | 5.00M | 11.60M | 100.00K | -1.30M | 300.00K | 200.00K | 400.00K | 200.00K |
| Income Before Tax | 56.26M | -16.48M | -9.29M | -3.52M | 21.33M | 31.72M | 41.03M | 20.32M | 8.83M | -4.27M | -11.96M | -16.51M | -9.71M | -3.50M | -8.44M | -8.75M | 4.29M | 9.06M | 9.72M | -559.64K | -1.11M | -3.34M | -3.70M | -12.72M | -3.20M | -1.90M | -22.50M | -300.00K | -18.50M | -15.60M | -14.70M | -7.20M | -4.90M | -2.90M | -2.60M |
| Income Before Tax Ratio | 13.87% | -4.25% | -3.98% | -2.05% | 13.80% | 17.45% | 24.56% | 15.85% | 7.38% | -4.01% | -12.09% | -18.80% | -11.86% | -4.66% | -10.95% | -12.30% | 5.19% | 13.30% | 14.01% | -1.04% | -2.74% | -10.44% | -11.36% | -42.26% | -31.68% | -19.39% | -239.36% | -0.44% | -370.00% | -325.00% | -445.45% | -240.00% | -128.95% | -80.56% | -81.25% |
| Income Tax Expense | 2.60M | 1.46M | 13.71M | 11.40M | 4.68M | 11.32M | 10.08M | 603.00K | 665.00K | 343.00K | -772.00K | -1.40M | -869.00K | 142.84K | -622.28K | 22.53M | 1.82M | 3.79M | -17.73M | -797.04K | 26.59K | -198.06K | 28.79K | 24.36K | 3.20M | 1.90M | 22.50M | 300.00K | 18.50M | 15.60M | 14.70M | 7.20M | 4.90M | 2.90M | 2.60M |
| Net Income | 53.66M | -17.94M | -23.00M | -14.92M | 16.66M | 20.40M | 30.95M | 19.72M | 8.17M | -4.61M | -11.19M | -15.12M | -8.84M | -3.50M | -7.81M | -31.28M | 2.47M | 5.27M | 27.45M | -559.64K | -1.14M | -3.34M | -3.73M | -12.75M | -3.20M | -1.90M | -22.50M | -300.00K | -18.50M | -15.60M | -14.70M | -7.20M | -4.90M | -2.90M | -2.60M |
| Net Income Ratio | 13.23% | -4.63% | -9.84% | -8.69% | 10.77% | 11.22% | 18.52% | 15.38% | 6.82% | -4.33% | -11.31% | -17.21% | -10.80% | -4.66% | -10.14% | -43.99% | 2.99% | 7.73% | 39.57% | -1.04% | -2.81% | -10.44% | -11.44% | -42.34% | -31.68% | -19.39% | -239.36% | -0.44% | -370.00% | -325.00% | -445.45% | -240.00% | -128.95% | -80.56% | -81.25% |
| EPS | 0.73 | -0.25 | -0.32 | -0.22 | 0.27 | 0.33 | 0.52 | 0.35 | 0.14 | -0.08 | -0.20 | -0.29 | -0.19 | -0.08 | -0.17 | -0.67 | 0.05 | 0.11 | 0.61 | -0.01 | -0.03 | -0.09 | -0.10 | -0.36 | -0.23 | -0.14 | -1.12 | -0.02 | -1.04 | -1.07 | -1.11 | -0.55 | -0.43 | -0.29 | -0.31 |
| EPS Diluted | 0.72 | -0.25 | -0.32 | -0.22 | 0.27 | 0.33 | 0.51 | 0.35 | 0.14 | -0.08 | -0.20 | -0.29 | -0.19 | -0.08 | -0.17 | -0.67 | 0.05 | 0.11 | 0.59 | -0.01 | -0.03 | -0.09 | -0.10 | -0.36 | -0.23 | -0.14 | -1.12 | -0.02 | -1.04 | -1.07 | -1.11 | -0.55 | -0.43 | -0.29 | -0.31 |
| Weighted Avg Shares Out | 73.35M | 72.51M | 71.98M | 67.51M | 61.68M | 61.11M | 59.05M | 55.62M | 56.40M | 55.95M | 55.56M | 51.46M | 46.91M | 46.19M | 45.88M | 46.55M | 46.33M | 45.91M | 45.11M | 44.46M | 39.79M | 37.58M | 36.87M | 35.00M | 13.91M | 13.57M | 20.10M | 18.90M | 17.79M | 14.61M | 13.24M | 13.09M | 11.40M | 10.00M | 8.39M |
| Weighted Avg Shares Out (Dil) | 74.39M | 72.51M | 71.98M | 67.51M | 62.17M | 62.53M | 61.02M | 56.51M | 56.85M | 55.95M | 55.56M | 51.46M | 46.91M | 46.19M | 45.88M | 46.55M | 46.88M | 46.58M | 46.15M | 44.46M | 39.79M | 37.58M | 36.87M | 35.00M | 13.91M | 13.57M | 20.10M | 18.90M | 17.79M | 14.61M | 13.24M | 13.09M | 11.40M | 10.00M | 8.39M |
OraSure to Announce Third Quarter 2023 Financial Results and Host Earnings Call on November 7th
BETHLEHEM, Pa., Oct. 23, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering third quarter 2023 financial results and certain business developments for 5:00 pm ET on Tuesday, November 7, 2023.
OraSure Technologies, Inc. (OSUR) Q2 2023 Earnings Call Transcript
OraSure Technologies, Inc. (NASDAQ:OSUR ) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ET Company Participants Jason Plagman – Vice President-Investor Relations Carrie Eglinton Manner – President and Chief Executive Officer Ken McGrath – Chief Financial Officer Conference...
OraSure Technologies (OSUR) Reports Q2 Loss, Tops Revenue Estimates
OraSure Technologies (OSUR) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to break-even earnings per share a year ago.
OraSure Reports Q2 ‘23 Revenue of $85.4 Million; Core Revenue Grows 3% Year-over-Year
InteliSwab® test revenue of $47.5 million in Q2 Q2 Core revenue of $37.9 million grew 4% sequentially and 3% year-over-year Q2 GAAP EPS of $(0.07); Q2 Non-GAAP EPS of $0.09 Grew cash balance to $185.9 million as o f June...
OraSure Technologies Elects Robert McMahon to the Board of Directors
BETHLEHEM, Pa., July 20, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, announced today the election of Robert W. McMahon, CMA, MBA,...
OraSure Technologies: As Good As It Gets
Today, we take our first look at OraSure Technologies, Inc., which has seen a huge and recent surge of revenues. However, this was almost entirely due to Covid-related sales which are projected to fall dramatically in the quarters ahead.
OraSure Technologies, Inc. (OSUR) Q1 2023 Earnings Call Transcript
OraSure Technologies, Inc. (NASDAQ:OSUR ) Q1 2023 Earnings Conference Call May 10, 2023 5:00 PM ET Company Participants Scott Gleason - Head of Investor Relations Carrie Manner - President & Chief Executive Officer Ken McGrath - Chief Financial Officer Conference...
OraSure Technologies (OSUR) Q1 Earnings and Revenues Beat Estimates
OraSure Technologies (OSUR) came out with quarterly earnings of $0.37 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to loss of $0.28 per share a year ago.
2023 First Quarter Earnings Conference Call Wednesday, May 10, 2023, 5:00 p.m. ET
BETHLEHEM, Pa., May 03, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2023 first quarter financial results and certain business developments for 5:00 p.m. ET (2:00 p.m. PT) on Wednesday, May...
Is OraSure Technologies (OSUR) Outperforming Other Medical Stocks This Year?
Here is how OraSure Technologies (OSUR) and Acadia Pharmaceuticals (ACAD) have performed compared to their sector so far this year.
Source: https://incomestatements.info
Category: Stock Reports